menu
    • menu

    Company profile for Anhui Ribobay Pharmaceutical Co.,Ltd

    Anhui Ribobay-PSE
    News
    Ribobay Pharma to start production of cGMP-level oligonucleotide

    18 Sep 2024

    // CRTMAGAZINE

    Ribobay Pharma boosts CRDMO offerings with Cytiva

    10 May 2024

    // PR NEWSWIRE

    FDA Approves First Medication for Obstructive Sleep Apnea

    21 Dec 2024

    // FDA

    DATA COMPILATION
    #PharmaFlow

    Ribobay VB RM

    Contact Supplier

    Website

    Pharma, Lab & Chemical Expo

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    SERVICES

    Key Products KEY SERVICES

    EXCIPIENTS

    EXCIPIENTS BY INGREDIENTS

    EXCIPIENTS BY APPLICATIONS

    PharmaCompass

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Related CompaniesRelated Companies

    About

    Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuzhou, within the Nanjing metropolitan area, Ribobay Pharmaceutical specializes in the therapeutic oligonucleotides CXO field. This strategic focus aligns with General Biol's broader expansion plans for its CXO business, making Ribobay a crucial component of the company's ventures in this domain.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Anhui Ribobay Pharmaceutical Co.,LtdChina Flag
    Country
    Country
    China
    Address
    Address
    Chemical Industry Concentration Zone, Quanjiao County, Chuzhou City, Anhui Pro...
    Telephone
    Telephone
    +86 5505361572
    Client Email
    Email
    tom.ding@ribobay.com
    Client Website
    Website
    http://www.ribobay.com/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/anhui-ribobay-pharmaceutical-co-ltd/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Email: sales@ribobay.com

    Events

    Webinars & Exhibitions

    A PHP Error was encountered

    Severity: Warning

    Message: Undefined variable $tile1

    Filename: tabs/exhibitions.php

    Line Number: 43

    Backtrace:

    File: /var/www/html/application/views/include/party/inc/tabs/exhibitions.php
    Line: 43
    Function: _error_handler

    File: /var/www/html/application/models/CmnPec.php
    Line: 1625
    Function: view

    File: /var/www/html/application/views/include/party/query.php
    Line: 575
    Function: create

    File: /var/www/html/application/views/include/party/indexNew.php
    Line: 70
    Function: include

    File: /var/www/html/application/views/commonNew.php
    Line: 445
    Function: include

    File: /var/www/html/application/controllers/PharmaServices.php
    Line: 4651
    Function: view

    File: /var/www/html/index.php
    Line: 224
    Function: require_once

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/anhui-ribobay-pharmaceutical-coltd-party-content-49200.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Oligonucleotide Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/anhui-ribobay-pharmaceutical-party-content-38014.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

    Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

    The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards.  Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio.  Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients.  The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 1790

    https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination

    #PharmaFlow by PHARMACOMPASS
    12 Sep 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Ribobay Pharma to start production of cGMP-level oligonucleotide
    Ribobay Pharma to start production of cGMP-level oligonucleotide

    18 Sep 2024

    // CRTMAGAZINE

    https://cleanroomtechnology.com/ribobay-pharma-uses-cytiva-s-first-flexfactory-platform-for

    CRTMAGAZINE
    18 Sep 2024
    Share Share
    Ribobay Pharma boosts CRDMO offerings with Cytiva
    Ribobay Pharma boosts CRDMO offerings with Cytiva

    10 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ribobay-pharma-boosts-crdmo-offerings-with-cytivas-first-flexfactory-platform-for-oligonucleotides-302142246.html

    PR NEWSWIRE
    10 May 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Givosiran

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Ribobay-Company-Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Inclisiran

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Ribobay-Company-Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Inotersen Sodium

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Ribobay-Company-Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Nusinersen Sodium

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Ribobay-Company-Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Patisiran

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Ribobay-Company-Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Viltolarsen

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Ribobay-Company-Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Volanesorsen

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Ribobay-Company-Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    Sales, Marketing, Registration

    Discover their expertise for : Sales, Marketing, Registration

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    API Development

    read-more
    read-more

    01

    CDMO FOR OLIGONUCLEOTIDE APIs

    China
    Contact Supplier
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Pharma Service : API & Drug Product Development

    Anhui Ribobay Pharmaceutical Co.,Ltd

    Ribobay offers small-scale to large-scale solid-phase synthesis of oligos with various modifications. Ribobay's service can support the RNAi therapeutics R&D from screening, pre-clinical to clinical stage and commercialization.

    arrow

    Category : API Development

    Sub Category : Oligonucleotide / Polynucleotide

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Pharma Service : API & Drug Product Development

    CDMO FOR OLIGONUCLEOTIDE APIs

    Ribobay offers small-scale to large-scale solid-phase synthesis of oligos with various modifications. Ribobay's service can support the RNAi therapeutics R&D from screening, pre-clinical to clinical stage and commercialization.

    arrow
    CDMO for Oligonucleotide APIs

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    02

    CUSTOM SYNTHESIS FOR OLIGONUCLEO...

    China
    Contact Supplier
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Pharma Service : API & Drug Product Development

    Anhui Ribobay Pharmaceutical Co.,Ltd

    Ribobay is involved in the custom synthesis of oligonucleotide active pharmaceutical ingredients (APIs). It also specializes in high-throughput oligonucleotide library synthesis and customized synthesis of toxicology batch samples for preclinical stages.

    arrow

    Category : API Development

    Sub Category : Custom Synthesis

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Pharma Service : API & Drug Product Development

    CUSTOM SYNTHESIS FOR OLIGONUCLEOTIDE APIs

    Ribobay is involved in the custom synthesis of oligonucleotide active pharmaceutical ingredients (APIs). It also specializes in high-throughput oligonucleotide library synthesis and customized synthesis of toxicology batch samples for preclinical stages.

    arrow
    Custom Synthesis for Oligonucleotide APIs

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    03

    OLIGONUCLEOTIDE API CLINICAL DEV...

    China
    Contact Supplier
    arrow
    Antibody Engineering
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Pharma Service : API & Drug Product Development

    Anhui Ribobay Pharmaceutical Co.,Ltd

    Ribobay offers contract development and manufacturing (CDMO) services for oligonucleotide APIs from preclinical research to commercialization. It supports the development of oligonucleotides for Phase I-III clinical studies.

    arrow

    Category : API Development

    Sub Category : Clinical Supply

    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRibobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Pharma Service : API & Drug Product Development

    OLIGONUCLEOTIDE API CLINICAL DEVELOPMENT

    Ribobay offers contract development and manufacturing (CDMO) services for oligonucleotide APIs from preclinical research to commercialization. It supports the development of oligonucleotides for Phase I-III clinical studies.

    arrow
    Oligonucleotide API Clinical Development

    Service
    Web Link

    Capabilities
    #ServicesBio

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Anhui Ribobay Pharmaceutical Popup full-view

    TOP RANKED SUPPLIER FOR:

    CDMO for Oligonucleotides
    full-view
    Oligonucleotide API Contract Manufacturing
    full-view

    Excipients

    Discover the DDS // excipients from this company

    Excipients by Ingredients

    Discover their expertise by components

    Excipients By applications

    Discover their expertise by claims

    ABOUT THIS PAGE

    Contact Anhui Ribobay Pharmaceutical Co.,Ltd and get a quotation

    Anhui Ribobay Pharmaceutical Co.,Ltd is a supplier offers 7 products (APIs, Excipients or Intermediates).

    Find a price of Givosiran bulk offered by Anhui Ribobay Pharmaceutical Co.,Ltd

    Find a price of Inclisiran bulk offered by Anhui Ribobay Pharmaceutical Co.,Ltd

    Find a price of Inotersen Sodium bulk offered by Anhui Ribobay Pharmaceutical Co.,Ltd

    Find a price of Nusinersen Sodium bulk offered by Anhui Ribobay Pharmaceutical Co.,Ltd

    Find a price of Patisiran bulk offered by Anhui Ribobay Pharmaceutical Co.,Ltd

    Find a price of Viltolarsen bulk offered by Anhui Ribobay Pharmaceutical Co.,Ltd

    Find a price of Volanesorsen bulk offered by Anhui Ribobay Pharmaceutical Co.,Ltd

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search